RecruitingPHASE1, PHASE2NCT02704858
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Studying Astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Neonc Technologies, Inc.
- Principal Investigator
- Thomas Chen, MD, PhDNeOnc Technologies Holdings, Inc.
- Intervention
- Perillyl alcohol(drug)
- Enrollment
- 49 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2026
Study locations (12)
- University of Southern California, Los Angeles, California, United States
- Saint John Cancer Institute, Santa Monica, California, United States
- Georgia Cancer Center (Augusta University), Augusta, Georgia, United States
- Ochsner Health, New Orleans, Louisiana, United States
- Atlantic Health (Overlook Medical Center), Summit, New Jersey, United States
- Northwell Health, New York, New York, United States
- Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Baylor Scott & White Health, Dallas, Texas, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- University of Washington Medical Center, Seattle, Washington, United States
- University of Wisconsin Hospital and Clinic, Madison, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02704858 on ClinicalTrials.govOther trials for Astrocytoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07552467Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant TumorsUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGEARLY PHASE1NCT07284069Senicapoc and Perampanel for Newly Diagnosed GlioblastomaAarhus University Hospital
- RECRUITINGPHASE2NCT05653635Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II StudyCentre Paul Strauss
- RECRUITINGPHASE1NCT07343986Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated GlioblastomaUniversity of Virginia
- RECRUITINGPHASE2NCT07417761Tuvusertib in Astrocytoma With ATRX MutationGrupo Español de Investigación en Neurooncología
- RECRUITINGNANCT06466031Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO]Copernicus Memorial Hospital
- RECRUITINGNANCT06930846HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)Dartmouth-Hitchcock Medical Center
- RECRUITINGPHASE3NCT07100730Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent GlioblastomaTelix Pharmaceuticals (Innovations) Pty Limited